Lanostane triterpenoids from Ganoderma hainanense J. D. Zhao

Peng, Xing‐Rong; Liu, Jie‐Qing; Xia, Jianjun; Wang, CuiFang; Li, XuYang; Deng, Yuanyuan; Bao, Ni-Man; Zhang, ZhiRun; Qiu, Ming‐Hua

doi:10.1016/j.phytochem.2014.10.009

Cited by 38 publications

(21 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The group evaluated the cytotoxicities of 16 compounds, including ganoderone A, lucidadiol, ganodermanontriol and 4,4,14a-trimethyl-3,7-dioxo-5a-chol-8-en-24-oic acid. Compounds 10, 12 and 17 (lucidadiol) showed inhibitory activities against MCF-7 cells [ 38 ]. Polysaccharides do not have direct cytotoxic activity against tumor cells, but do stimulate the immune response.…”

Section: In Vitro Studiesmentioning

confidence: 99%

Ganoderma spp.: A Promising Adjuvant Treatment for Breast Cancer

et al. 2017

View full text Add to dashboard Cite

For the past several decades, cancer patients in the U.S. have chosen the use of natural products as an alternative or complimentary medicine approach to treat or improve their quality of life via reduction or prevention of the side effects during or after cancer treatment. The genus Ganoderma includes about 80 species of mushrooms, of which several have been used for centuries in traditional Asian medicine for their medicinal properties, including anticancer and immunoregulatory effects. Numerous bioactive compounds seem to be responsible for their healing effects. Among the approximately 400 compounds produced by Ganoderma spp., triterpenes, peptidoglycans and polysaccharides are the major physiologically-active constituents. Ganoderma anticancer effects are attributed to its efficacy in reducing cancer cell survival and growth, as well as by its chemosensitizing role. In vitro and in vivo studies have been conducted in various cancer cells and animal models; however, in this review, we focus on Ganoderma's efficacy on breast cancers. Evidence shows that some species of Ganoderma have great potential as a natural therapeutic for breast cancer. Nevertheless, further studies are needed to investigate their potential in the clinical setting and to translate our basic scientific findings into therapeutic interventions for cancer patients.

show abstract

Section: In Vitro Studiesmentioning

confidence: 99%

Ganoderma spp.: A Promising Adjuvant Treatment for Breast Cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Extracting Ganoderma spores oil from broken spores by supercritical CO 2 extraction technology has been developed in recent years, and several studies have since examined the antitumor effect of Ganoderma spores oil (17,18). In the present study, a G1 arrest was detected in K562 cells treated with Ganoderma spores oil.…”

Section: Discussionmentioning

confidence: 47%

Antitumor effects and mechanisms of Ganoderma extracts and spores oil

Chen

Li³

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Ganoderma lucidum is a popular herbal medicine used in China to promote health. Modern studies have disclosed that the active ingredients of Ganoderma can exhibit several effects, including antitumor effects and immunomodulation. The present study evaluated the antitumor effects of self-prepared Ganoderma extracts and spores oil, and investigated the possible underlying mechanisms by observing the effects of the extracts and oil on topoisomerases and the cell cycle. The results showed that Ganoderma extracts and spores oil presented dose-dependent inhibitory effects on tumor cells. The half maximal inhibitory concentration (IC 50 ) values of Ganoderma extracts on HL60, K562 and SGC-7901 cells for 24 h were 0.44, 0.39 and 0.90 mg/ml, respectively; for Ganoderma spores oil, the IC 50 values were 1.13, 2.27 and 6.29 mg/ml, respectively. In the in vivo study, the inhibitory rates of Ganoderma extracts (4 g/kg/d, intragastrically) on S180 and H22 cells were 39.1 and 44.6%, respectively, and for Ganoderma spores oil (1.2 g/kg/d, intragastrically) the inhibitory rates were 30.9 and 44.9%, respectively. Ganoderma extracts and spores oil inhibited the activities of topoisomerase I and II. Ganoderma spores oil was shown block the cell cycle at the transition between the G1 and S phases and induce a marked decrease in cyclin D1 levels in K562 cells, with no significant change in cyclin E level. These results suggest that the Ganoderma extracts and spores oil possessed antitumor effects in the in vitro and in vivo studies. The antitumor mechanisms of the extracts and spores oil were associated with inhibitory effects on topoisomerase I and II activities, and for Ganoderma spores oil, the antitumor effects may also be associated with decreased cyclin D1 levels, thus inducing G1 arrest in the cell cycle.

show abstract

“…Chemical studies of the chloroform extract of G. lingzhi afforded seven compounds (1)(2)(3)(4)(5)(6)(7), of which six were identified as lucidumol A (2), ergosterol palmitate (3), ergosta-7,22-dien-3b-yl palmitate (4), ergosterol (5), ergosterol peroxide (6) and ganoderic acid A (7 -12) with d c 151.1, assigned to C-8. The above evidence indicated the presence of an 11-ketone-8-ene structural fragment.…”

Section: Resultsmentioning

confidence: 99%

Lucidumol C, a new cytotoxic lanostanoid triterpene from Ganoderma lingzhi against human cancer cells

et al. 2016

View full text Add to dashboard Cite

A new oxygenated lanostane-type triterpene, named lucidumol C, together with six known compounds, was isolated from the chloroform extract of the fruiting bodies of Ganoderma lingzhi. Structures were established based on extensive spectroscopic and chemical studies. Potential cytotoxic activities of the isolated compounds were evaluated against human colorectal carcinoma (HCT-116, Caco-2), human liver carcinoma (HepG2), and human cervical carcinoma (HeLa) cell lines using WST-1 reagent. Selectivity was evaluated using normal human fibroblast cells (TIG-1 and HF19). Among the compounds, lucidumol C showed potent selective cytotoxicity against HCT-116 cells with an IC50 value of 7.86 ± 4.56 µM and selectivity index (SI) >10 with remarkable cytotoxic activities against Caco-2, HepG2 and HeLa cell lines.

show abstract

Lanostane triterpenoids from Ganoderma hainanense J. D. Zhao

Cited by 38 publications

References 24 publications

Ganoderma spp.: A Promising Adjuvant Treatment for Breast Cancer

Ganoderma spp.: A Promising Adjuvant Treatment for Breast Cancer

Antitumor effects and mechanisms of Ganoderma extracts and spores oil

Lucidumol C, a new cytotoxic lanostanoid triterpene from Ganoderma lingzhi against human cancer cells

Contact Info

Product

Resources

About